TSC22 domain family member 4Genealiases: THG-1 · THG1 · TILZ2
Q-omics provides the consensus-scored TSC22D4 profile across patient tissues and cancer cell-line models. TSC22D4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TSC22D4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TSC22D4 RNA expression shows 16,974 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TSC22D4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSC22D4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSC22D4 survival associations across molecular data types. TSC22D4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSC22D4 RNA expression–survival associations across cancer types. High TSC22D4 expression shows unfavorable associations in KIRC, OV, LIHC, READ and COAD, but favorable associations in THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for TSC22D4 RNA expression.
This table summarizes TSC22D4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSC22D4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSC22D4 shows lower tumor expression in READ and higher tumor expression in THCA, LIHC, CHOL, STAD and ESCA. The THCA box plot shows higher TSC22D4 RNA expression in tumor versus normal tissue (log2 FC = +0.488, t-test p < 0.001).
This table shows molecular features associated with TSC22D4 in patient tissues and cancer cell lines. In patient samples, TSC22D4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSC22D4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
